Retatrutide for obesity
Reported large average weight reductions over 48 weeks.
Phase 2; investigational and not long-term outcome evidence.
Original source ↗Loading TrenasCycles…
TrenasCycles
Loading TrenasCycles…
Investigational metabolic peptide
LY3437943
Retatrutide is discussed for appetite control and major weight loss. It targets three hormone signals, adding glucagon activity to the two targeted by tirzepatide. Weight-loss trials are promising, but it is still experimental. Nausea, vomiting, bowel problems and a faster heart rate are the main concerns.
Assigned target doses in a phase 2 trial of adults with obesity or overweight plus a related condition; not a dosing recommendation or escalation schedule.
Phase-2 obesity and type-2-diabetes trials reported substantial average weight reduction and improved glycemia, with gastrointestinal and heart-rate effects among safety findings.
Nausea, vomiting, diarrhea/constipation, appetite suppression, heart-rate increase and unknown longer-term risks; product-quality risk outside trials.
Weight trajectory, hydration/nutrition, glucose when relevant, GI symptoms and heart rate under research/clinical oversight.
Investigational; phase-2 publications show weight and glycemic effects, while ongoing trials determine longer-term benefit and safety. Verify current status before publication.
Other aliases: LY3437943 · reta
Reported large average weight reductions over 48 weeks.
Phase 2; investigational and not long-term outcome evidence.
Original source ↗Improved glycemia and weight measures.
Phase 2; selected population.
Original source ↗Ongoing/registered phase-3 evaluation.
Registry record; results may not yet be complete.
Original source ↗